The efficacy of re-challenge of denosumab in postmenopausal women with hormone receptor-positive breast cancer who are currently on or will iniate an aromatase inhibitor in the adjuvant setting
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Jun 2018
Price : $35 *
At a glance
- Drugs Denosumab (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- 10 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 21 Jan 2018 Status changed from not yet recruiting to recruiting.
- 11 Dec 2017 New trial record